ADVERTISEMENT
Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis
Among JAK inhibitor-treatment-naïve patients with myelofibrosis, the combination of navitoclax and ruxolitinib reduced splenomegaly in several high-risk groups known to confer poor prognosis, according to a recent study. Notably, there was a reduction in bone marrow fibrosis (BMF) and variant allele frequency (VAF) of driver mutations for the driver mutation JAK2V617 in patients with myelofibrosis in the study. These results are suggestive of evidence of disease modification with the combination of navitoclax and ruxolitinib.
These findings were presented at the 2022 American Society of Hematology (ASH) Annual Meeting & Exposition in New Orleans, LA, by Francesco Passamonti, MD, Division of Hematology, University of Insubria, Varese, Italy.
Source:
Passamonti F, Foran J, Tandra A, et al. The Combination of Navitoclax and Ruxolitinib in JAK Inhibitor-Naïve Patients with Myelofibrosis Mediates Responses Suggestive of Disease Modification. Presented at the ASH Annual Meeting & Exposition; December 10-13, 2022; New Orleans, LA, and virtual. Abstract 237.
